|
1
|
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
|
Nat Med
|
2006
|
9.07
|
|
2
|
Tyrosine kinases as targets for cancer therapy.
|
N Engl J Med
|
2005
|
6.24
|
|
3
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
4
|
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
|
Nat Genet
|
2004
|
3.96
|
|
5
|
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression.
|
Nature
|
2003
|
3.77
|
|
6
|
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
|
J Clin Invest
|
2009
|
3.55
|
|
7
|
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
|
Cancer Cell
|
2011
|
3.49
|
|
8
|
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
|
Nat Rev Cancer
|
2007
|
3.32
|
|
9
|
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
|
Nat Med
|
2006
|
2.69
|
|
10
|
Differential regulation of myeloid leukemias by the bone marrow microenvironment.
|
Nat Med
|
2013
|
2.48
|
|
11
|
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
|
PLoS One
|
2006
|
2.42
|
|
12
|
Critical role for Gab2 in transformation by BCR/ABL.
|
Cancer Cell
|
2002
|
2.42
|
|
13
|
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
|
Proc Natl Acad Sci U S A
|
2002
|
2.19
|
|
14
|
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
|
Proc Natl Acad Sci U S A
|
2002
|
2.13
|
|
15
|
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
|
Blood
|
2012
|
1.67
|
|
16
|
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.
|
Cancer Cell
|
2004
|
1.52
|
|
17
|
Right on target: eradicating leukemic stem cells.
|
Trends Mol Med
|
2007
|
1.49
|
|
18
|
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.
|
EMBO J
|
2002
|
1.45
|
|
19
|
Autoinhibition of Bcr-Abl through its SH3 domain.
|
Mol Cell
|
2003
|
1.43
|
|
20
|
Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
|
J Neurosci
|
2005
|
1.35
|
|
21
|
Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis.
|
Circ Res
|
2008
|
1.14
|
|
22
|
Production of replication-defective retrovirus by transient transfection of 293T cells.
|
J Vis Exp
|
2007
|
1.04
|
|
23
|
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
|
Mol Cell Biol
|
2004
|
1.02
|
|
24
|
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
|
Blood
|
2002
|
1.01
|
|
25
|
Ubiquitous and uniform in vivo fluorescence in ROSA26-EGFP BAC transgenic mice.
|
Genesis
|
2007
|
0.98
|
|
26
|
CDK6 kinase activity is required for thymocyte development.
|
Blood
|
2011
|
0.96
|
|
27
|
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.
|
Transfusion
|
2012
|
0.94
|
|
28
|
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
|
Blood Cells Mol Dis
|
2005
|
0.93
|
|
29
|
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
|
Curr Opin Hematol
|
2011
|
0.93
|
|
30
|
Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.
|
Blood
|
2014
|
0.92
|
|
31
|
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.
|
Hematology Am Soc Hematol Educ Program
|
2013
|
0.91
|
|
32
|
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.
|
Blood
|
2011
|
0.90
|
|
33
|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
|
Am J Hematol
|
2012
|
0.87
|
|
34
|
Retracted
GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38.
|
Proc Natl Acad Sci U S A
|
2009
|
0.87
|
|
35
|
Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.
|
Leuk Lymphoma
|
2011
|
0.87
|
|
36
|
Bedside to bench: interfering with leukemic stem cells.
|
Nat Med
|
2008
|
0.86
|
|
37
|
IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
|
Blood
|
2014
|
0.85
|
|
38
|
JAKing up hematopoietic proliferation.
|
Cancer Cell
|
2005
|
0.84
|
|
39
|
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
|
Leuk Lymphoma
|
2014
|
0.84
|
|
40
|
Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.
|
Blood
|
2004
|
0.84
|
|
41
|
Signal transduction in the chronic leukemias: implications for targeted therapies.
|
Curr Hematol Malig Rep
|
2013
|
0.84
|
|
42
|
Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
|
Blood
|
2011
|
0.84
|
|
43
|
Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease.
|
Proc Natl Acad Sci U S A
|
2008
|
0.79
|
|
44
|
New insights into the normal and leukemic stem cell niche: a timely review.
|
Cytometry B Clin Cytom
|
2013
|
0.78
|
|
45
|
Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders.
|
Curr Protoc Pharmacol
|
2008
|
0.77
|
|
46
|
Retraction for Zhong et al. GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38.
|
Proc Natl Acad Sci U S A
|
2012
|
0.77
|
|
47
|
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
48
|
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
|
Am J Hematol
|
2011
|
0.75
|